How does an EFS differ from a traditional IDE study?

An EFS typically involves less extensive non-clinical evidence to support the initial human use and allows for iterative device modifications during the study. Traditional IDEs generally require more comprehensive non-clinical data and have less flexibility for design changes during the trial.

Can device modifications be made during an EFS?

Yes, a key feature of an EFS is the allowance for iterative device modifications based on early clinical feedback, which can be implemented more readily than in traditional clinical trials. These modifications must be documented and reviewed according to the study protocol and regulatory requirements.

Is an EFS always a first-in-human study?

While often a first-in-human study, an EFS may also involve early clinical experience with a modification to an existing device for a new indication or patient population, where the modification significantly changes the device's safety or performance characteristics.

All terms

Clinical & TrialsClinical Evidence Global Markets Startup LifecycleEFS

Early Feasibility Study

FDA program enabling early human evaluation of novel devices with limited preclinical data and iterative design.

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

Definition

EFSs allow first-in-human use of a novel device based on less nonclinical evidence than a traditional IDE, with allowances for iterative device modifications during the study. FDA's 2013 guidance on early feasibility studies describes the program, which enrolls a small number of subjects, often around 10, at an early design stage. FDA allows a lighter nonclinical package when justified, and design changes during the study can often be made with notice or quick review. The program aims to bring early device innovation back to the US.

What the regulation says

The FDA provides specific guidance on Early Feasibility Studies, outlining criteria for device selection, non-clinical data requirements, and the iterative nature of device modifications. This approach is intended to accelerate the development of novel medical devices by allowing earlier human experience (FDA, "Guidance for Industry and FDA Staff: Early Feasibility Studies for Medical Devices").

What this means in practice

Strategically valuable for breakthrough cardiovascular, neuro, and surgical devices needing early clinical signal to inform design freeze.

Examples

A MedTech company is developing a novel neurostimulation device for refractory epilepsy and conducts an EFS to assess its initial safety and thermodynamic stability in a small cohort of patients.
An EFS is initiated for a new cardiovascular stent design to evaluate acute deployment success and early patency rates, allowing real-time adjustments to the delivery system.
A surgical robotics firm performs an EFS to test a new haptic feedback system in real surgical scenarios, making minor software adjustments based on surgeon input.

Common pitfalls

•A common pitfall is misunderstanding the reduced non-clinical evidence requirements, which are still substantial and must justify the proposed human use.
•Another mistake is failing to adequately plan for iterative device modifications, leading to delays in regulatory approvals.
•Companies often underestimate the importance of strong clinical protocol design and robust data collection in EFSs.
•Inadequate consideration of patient safety measures during the iterative design process can lead to serious compliance issues.

Frequently asked questions

The primary goal is to gather initial clinical experience with a novel medical device, often a first-in-human use, to inform device design and development. It aims to evaluate the device's safety and basic functionality in a limited patient population.

Grouped by theme

Editor's picks

· Hand-selected related concepts

Clinical & Trials

Feasibility Study

Small clinical study evaluating initial safety, usability, and design parameters of an investigational device.

Clinical & Trials

First-in-Human Study(FIH)

First clinical use of a device or therapy in humans, often outside the U.S. before a U.S. EFS.

Clinical & Trials

Investigational Device Exemption(IDE)

FDA authorization to use an investigational device in a clinical study.

More in Clinical & Trials

· Same category

Clinical & Trials

Adaptive Trial Design

Trial design that pre-specifies opportunities to modify aspects (sample size, arms, endpoints) based on interim data.

Clinical & Trials

Adverse Event(AE)

Any untoward medical occurrence in a subject, whether or not related to the device.

Clinical & Trials

ALCOA+

Data integrity principles: Attributable, Legible, Contemporaneous, Original, Accurate (plus Complete, Consistent, Enduring, Available).

Clinical & Trials

Analytical Sensitivity

An IVD's ability to detect small quantities of an analyte.

Cited by

Where this term appears across MedTech Terms.

Ecosystems (3)

Latest in MedTech

Sources

3 sources

Sources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

Tier 1Binding law and standards· 1Tier 2Regulator guidance and consensus· 2

Link health: 3 verified· last checked 2026-06-20

FDA·2ISO·1

Inline markers like [1] jump to the matching reference above.

My progress

All terms0 / 513

Clinical & Trials0 / 52

Saved on this device, and to your account when signed in. View studied terms

Full glossary

Browse all terms A to Z, each with a short definition.

On this term

Category: Clinical & Trials
Acronym: EFS
Sources: 3
Updated: 5/5/2026

Compare with another term

Learn in 60 seconds

FDA program enabling early human evaluation of novel devices with limited preclinical data and iterative design.

·Strategically valuable for breakthrough cardiovascular, neuro, and surgical devices needing early clinical signal to inform design freeze.
·FDA's 2013 guidance on early feasibility studies describes the program, which enrolls a small number of subjects, often around 10, at an early design stage.
·FDA allows a lighter nonclinical package when justified, and design changes during the study can often be made with notice or quick review.

Remember this

Watch out: A common pitfall is misunderstanding the reduced non-clinical evidence requirements, which are still substantial and must justify the proposed human use.

Related terms

You may also need

Auto-suggested from Clinical & Trials and shared keywords.

All Clinical & Trials terms

From the Blue Goat network

Related resources and services on this topic.

MedTech Launchpad
MedTech funding rounds, accelerators, and launch resources.